title: Thalidomide metabolism and hydrolysis: mechanisms and implications.
abstract: Despite its controversial past, thalidomide is currently under investigation for the treatment of several disease types, ranging from inflammatory conditions to cancer. The mechanism of action of thalidomide is complex and not yet fully understood, but there is some evidence to suggest that metabolism may play a role. Consequently, there has been a considerable effort to characterize the metabolism of thalidomide in recent years. Thalidomide undergoes biotransformation by non-enzymatic hydrolysis and enzyme-mediated hydroxylation to form a multitude of metabolites. Metabolite identification and reaction phenotyping studies have been performed and will be discussed in this review in addition to interspecies differences in thalidomide metabolism.
authors.affiliation: Clinical Pharmacology Research Core, SAIC-Frederick, Inc., NCI-Frederick, Maryland, 21702, USA.
authors.forename: Erin R
authors.initials: ER
authors.lastname: Lepper
authors.forename: Nicola F
authors.initials: NF
authors.lastname: Smith
authors.forename: Michael C
authors.initials: MC
authors.lastname: Cox
authors.forename: Charity D
authors.initials: CD
authors.lastname: Scripture
authors.forename: William D
authors.initials: WD
authors.lastname: Figg
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology; D003577:Cytochrome P-450 Enzyme System / Q000502:physiology; D006801:Humans; D006868:Hydrolysis; D010597:Pharmacogenetics; D013792:Thalidomide / Q000378:metabolism* / Q000494:pharmacology
chemical_list: D020533:Angiogenesis Inhibitors; D000893:Anti-Inflammatory Agents; D052246:Cyclooxygenase 2 Inhibitors; D013792:Thalidomide; D003577:Cytochrome P-450 Enzyme System